Neuroprotective effect of formononetin in ameliorating learning and memory impairment in mouse model of Alzheimer’s disease

References

• Kugaevskaya EV. Angiotensin converting enzyme and Alzheimer’s disease. Biochem (Moscow) Suppl Series B: Biomed Chem. 2012;6(1):11–22.
   Google Scholar
• Zhang L, Ma Q, Yang W, et al. Recombinant DNA vaccine against neurite outgrowth inhibitors attenuates behavioral deficits and decreases Abeta in an Alzheimer’s disease mouse model. Neuropharmacology. 2013;70:200–210.10.1016/j.neuropharm.2012.10.023
   PubMed Web of Science ®Google Scholar
• Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. Lancet Neurol. 2013;12(1):92–104.10.1016/S1474-4422(12)70259-4
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28(4):202–208.10.1016/j.tins.2005.02.001
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer’s Abeta peptide: the many roads to perdition. Neuron. 2004;43(5):605–608.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med. 2010;16(12):1370–1371.10.1038/nm1210-1370
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723–738.
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35(11_Suppl_1):2628–2631.10.1161/01.STR.0000143452.85382.d1
   PubMed Web of Science ®Google Scholar
• Wang D, Di X, Fu L, et al. Analysis of serum beta-amyloid peptides, alpha2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer’s disease. NeuroReport. 2016;27(15):1114–1119.10.1097/WNR.0000000000000661
   PubMed Web of Science ®Google Scholar
• Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112(4):405–415.10.1007/s00401-006-0115-3
   PubMed Web of Science ®Google Scholar
• Tokuda T, Calero M, Matsubara E, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem J. 2000;348(Pt 2):359–365.
   PubMed Web of Science ®Google Scholar
• Qosa H, Abuasal BS, Romero IA, et al. Differences in amyloid-beta clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology. 2014;79:668–678.10.1016/j.neuropharm.2014.01.023
   PubMed Web of Science ®Google Scholar
• Qosa H, Mohamed LA, Al Rihani SB, et al. High-throughput screening for identification of blood-brain barrier integrity enhancers: a drug repurposing opportunity to rectify vascular amyloid toxicity. J Alzheimers Dis. 2016;53(4):1499–1516.10.3233/JAD-151179
   PubMed Web of Science ®Google Scholar
• Kafa H, Wang JT, Rubio N, et al. Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivo. J Control Release. 2016;225:217–229.10.1016/j.jconrel.2016.01.031
   PubMed Web of Science ®Google Scholar
• Kanekiyo T, Cirrito JR, Liu CC, et al. Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci. 2013;33(49):19276–19283.10.1523/JNEUROSCI.3487-13.2013
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Yamada S, Holtzman D, et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med. 2000;6(7):718–718.10.1038/77397
   Web of Science ®Google Scholar
• Cai Z, Liu N, Wang C, et al. Role of RAGE in Alzheimer’s disease. Cell Mol Neurobiol. 2016;36(4):483–495.10.1007/s10571-015-0233-3
   PubMed Web of Science ®Google Scholar
• Meneghini V, Bortolotto V, Francese MT, et al. High-mobility group box-1 protein and beta-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-kappa B axis: relevance for Alzheimer’s disease. J Neurosci. 2013;33(14):6047–6059.10.1523/JNEUROSCI.2052-12.2013
   PubMed Web of Science ®Google Scholar
• Tan X, Gu J, Zhao B, et al. Ginseng improves cognitive deficit via the RAGE/NF-kappaB pathway in advanced glycation end product-induced rats. J Ginseng Res. 2015;39(2):116–124.10.1016/j.jgr.2014.09.002
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim H, Kim YH, et al. Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2012;22(24):7555–7561.10.1016/j.bmcl.2012.10.022
   PubMed Web of Science ®Google Scholar
• Liu CH, Tsai CH, Li TC, et al. Effects of the traditional Chinese herb Astragalus membranaceus in patients with poststroke fatigue: A double-blind, randomized, controlled preliminary study. J Ethnopharmacol. 2016;194:954–962.10.1016/j.jep.2016.10.058
   PubMed Web of Science ®Google Scholar
• Zhu H, Zou L, Tian J, et al. Protective effects of sulphonated formononetin in a rat model of cerebral ischemia and reperfusion injury. Planta Med. 2014;80(4):262–268.
   PubMed Web of Science ®Google Scholar
• Liang K, Ye Y, Wang Y, et al. Formononetin mediates neuroprotection against cerebral ischemia/reperfusion in rats via downregulation of the Bax/Bcl-2 ratio and upregulation PI3 K/Akt signaling pathway. J Neurol Sci. 2014;344(1–2):100–104.10.1016/j.jns.2014.06.033
   PubMed Web of Science ®Google Scholar
• Li WZ, Wu WY, Huang DK, et al. Protective effects of astragalosides on dexamethasone and Abeta25-35 induced learning and memory impairments due to decrease amyloid precursor protein expression in 12-month male rats. Food Chem Toxicol. 2012;50(6):1883–1890.10.1016/j.fct.2012.03.064
   PubMed Web of Science ®Google Scholar
• Li Z, Dong X, Zhang J, et al. Formononetin protects TBI rats against neurological lesions and the underlying mechanism. J Neurol Sci. 2014;338(1–2):112–117.10.1016/j.jns.2013.12.027
   PubMed Web of Science ®Google Scholar
• Wu J, Fu B, Lei H, et al. Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice. Neuroscience. 2016;332:160–169.10.1016/j.neuroscience.2016.06.049
   PubMed Web of Science ®Google Scholar
• Jurgens HA, Amancherla K, Johnson RW. Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice. J Neurosci. 2012;32(12):3958–3968.10.1523/JNEUROSCI.6389-11.2012
   PubMed Web of Science ®Google Scholar
• Gupta V, Gupta VB, Chitranshi N, et al. One protein, multiple pathologies: multifaceted involvement of amyloid beta in neurodegenerative disorders of the brain and retina. Cell Mol Life Sci. 2016;73(22):4279–4297.10.1007/s00018-016-2295-x
   PubMed Web of Science ®Google Scholar
• Storck SE, Meister S, Nahrath J, et al. Endothelial LRP1 transports amyloid-beta(1-42) across the blood-brain barrier. J Clin Invest. 2016;126(1):123–136.
   PubMed Web of Science ®Google Scholar
• Kim DK, Park JD, Choi BS. Mercury-induced amyloid-beta (Abeta) accumulation in the brain is mediated by disruption of Abeta transport. J Toxicol Sci. 2014;39(4):625–635.10.2131/jts.39.625
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28(5):639–647.10.1016/j.neurobiolaging.2006.03.013
   PubMed Web of Science ®Google Scholar
• Lehrer S. Nasal NSAIDs for Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2014;29(5):401–403.10.1177/1533317513518658
   PubMed Web of Science ®Google Scholar
• Morin JP, Cerón-Solano G, Velázquez-Campos G, et al. Spatial memory impairment is associated with intraneural amyloid-beta immunoreactivity and dysfunctional arc expression in the hippocampal-CA3 region of a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2016;51(1):69–79.10.3233/JAD-150975
   PubMed Web of Science ®Google Scholar